ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - ADC Therapeutics reported a quarterly loss of $0.3 per share, better than the Zacks Consensus Estimate of a loss of $0.4, and an improvement from a loss of $0.42 per share a year ago, resulting in an earnings surprise of +25.00% [1] - The company posted revenues of $16.43 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.03%, although this represents a decline from year-ago revenues of $18.46 million [2] - Over the last four quarters, ADC Therapeutics has exceeded consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] Stock Outlook - ADC Therapeutics shares have increased approximately 103% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $19.15 million, and for the current fiscal year, it is -$1.67 on revenues of $77.13 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which ADC Therapeutics belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]